Minneapolis Clinical Trials

2104 Study (Renal)

Study 2104 is evaluating the safety and tolerability of a single dose of the investigational drug in individuals with renal impairment compared with individuals without renal impairment.

4 nights

The investigational drug will be orally administered.

There are two screening appointments prior to the inpatient stay. Compensation for study participation may be provided for time and travel up to $1,450.

This study has been approved by an independent ethics committee.

Call Jenna at 651-724-0500 or register your interest to discuss your eligibility today!


Biological Sex Males or Females
Age 18 - 82 years old
BMI 18 - 40
Medical Conditions Must be stable in opinion of study doctor
Medications Must be stable in opinion of study doctor
Smoking History Must smoke < 10 cigarettes per day